CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 142 target
Drug / intervention
AtriCure ISOLATOR Synergy Surgical Ablation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05280093
NCT05280093N/AActiveOn TrackUpdated 4mo ago
CompareCT.gov

Hybrid Epicardial and Endocardial Sinus Node Sparing Ablation Therapy for Inappropriate Sinus Tachycardia

AtriCure, Inc.·interventional·Posted Mar 15, 2022·Updated Mar 2, 2026

In Brief

A clinical study evaluating AtriCure ISOLATOR Synergy Surgical Ablation System for Inappropriate Sinus Tachycardia. Active but no longer recruiting, targeting 142 participants across 27 sites in 6 countries.

Detailed Summary

Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInappropriate Sinus Tachycardia
CountriesBelgium, Italy, Netherlands, Poland, United Kingdom, United States
Collaborators--

Timeline

N/AActive
202320242025202620272028
First PostedMar 15, 2022
Enrollment StartMay 31, 2022
Primary CompletionFeb 1, 2027
Study CompletionFeb 1, 2028
TodayJul 1, 2026
Enrollment to primary: 4.7 yearsPosted 4.3 years agoPrimary completion in 7 months

Interventions

AtriCure ISOLATOR Synergy Surgical Ablation Systemdevice

Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System